8-K: Savara Presents Strong MOLBREEVI Data, Expanded Market

Savara Inc. updated its corporate presentation, showcasing positive Phase 3 IMPALA-2 trial results for MOLBREEVI in autoimmune PAP and an expanded U.S. market opportunity.

Summary

• Savara Inc. updated its corporate presentation, highlighting the investigational drug MOLBREEVI (molgramostim inhalation solution) for autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).
• MOLBREEVI demonstrated clinically meaningful positive Phase 3 IMPALA-2 results, addressing the pathophysiology of autoimmune PAP with a favorable benefit/risk profile and good tolerability.
• The primary endpoint, change from baseline to Week 24 in DLco% (hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide), showed a statistically significant improvement (p=0.0007) for MOLBREEVI versus placebo.
• Secondary endpoints also showed significant improvements, including DLco% at Week 48 (p=0.0008), SGRQ Total Score at Week 24 (p=0.0072), and nominally significant improvements in SGRQ Activity Score at Week 24 (p=0.0149) and Exercise Capacity at Week 48 (p=0.0234).
• MOLBREEVI treatment led to a reduction in pulmonary surfactant burden, as evidenced by a statistically significant decrease in Ground Glass Opacity (GGO) score at Week 24 (p=0.0004) in a post-hoc analysis.
• The company plans to resubmit its Biologics License Application (BLA) for MOLBREEVI in the U.S. in December 2025, with Fuji as the drug substance manufacturer.
• New U.S. claims data analysis indicates the autoimmune PAP market is approximately 50% larger than previously projected, with an estimated 5,542 autoimmune PAP patients in the U.S., up from 3,637.
• Savara projects a total addressable market (TAM) of over $2 billion in the U.S. for autoimmune PAP, with potential orphan rare disease pricing power of $400K-$500K annually.
• As of June 30, 2025, Savara reported approximately $146 million in cash and short-term investments, providing a cash runway into Q1 2027.

Sentiment

Score: 9

Explanation: The filing presents highly positive Phase 3 clinical trial results for MOLBREEVI, demonstrating significant efficacy and a favorable safety profile for an unmet medical need. Coupled with a substantially expanded market opportunity and a strong cash position, the overall sentiment is very positive, indicating strong potential for future growth and commercial success.

Positives

• MOLBREEVI achieved statistically significant improvements in the primary endpoint (DLco% at Week 24, p=0.0007) and key secondary endpoints in the Phase 3 IMPALA-2 trial.
• The drug was well-tolerated with a low treatment discontinuation rate (3%) and no drug-related adverse events leading to discontinuation.
• MOLBREEVI demonstrated a reduction in pulmonary surfactant burden, a key pathological feature of autoimmune PAP, as shown by GGO score improvement (p=0.0004).
• The updated U.S. claims data analysis reveals a ~50% larger addressable market for autoimmune PAP, increasing the commercial opportunity.
• Strong stakeholder support was reported, with 83% of U.S. pulmonologists likely to prescribe MOLBREEVI and 87% of U.S. payers intending to cover it with typical prior authorization criteria.
• Savara holds a strong financial position with ~$146 million in cash and short-term investments, providing a cash runway into Q1 2027.
• MOLBREEVI has received multiple regulatory designations, including U.S. Orphan Drug, Fast Track, and Breakthrough Therapy, and European Orphan Drug and UK Innovation Passport, which could expedite approval and provide market exclusivity.
• The company has a robust intellectual property strategy, including pending patent applications for drug formulation and methods of use, and an exclusive worldwide license to the proprietary eFlow Nebulizer System.

Risks

• Actual results and timing of events could differ materially from forward-looking statements due to various risks and uncertainties.
• Risks are associated with the ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP.
• Uncertainties exist regarding the impact of widespread health concerns and geopolitical conditions on business and operations.
• Risks and uncertainties are associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations.
• The ability to successfully conduct clinical trials for product candidates is a risk.
• The availability of sufficient resources and the timing and ability of Savara to raise additional capital as needed to fund continued operations is a risk.
• The long-term negative impact (potential lung damage) of repeated Whole Lung Lavage (WLL) procedures, the current standard of care, is unknown.

Future Outlook

Savara plans to resubmit its Biologics License Application (BLA) for MOLBREEVI in the U.S. in December 2025, with potential approval following. The company is actively advancing commercial launch planning activities, including expanding disease awareness, building infrastructure, and hiring key commercial roles. They anticipate a durable revenue stream with unlikely biosimilar competition due to 12-year biologic exclusivity upon approval.

Management Comments

• MOLBREEVI has clinically meaningful positive Phase 3 results that suggest it may address the pathophysiology of autoimmune PAP.
• The company is committed to expanding awareness of autoimmune PAP and educating on the importance of early testing.
• Critical capabilities are being built to facilitate access to MOLBREEVI post-approval, including a single specialty pharmacy model and a patient support program (MyMolbreevi).
• The updated U.S. claims data analysis confirms a significantly larger market opportunity for MOLBREEVI than previously estimated.

Industry Context

Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) is a rare, long-term, chronic lung disease with no approved drugs in the U.S. or Europe. The only current treatment option is Whole Lung Lavage (WLL), an invasive procedure that does not correct the underlying pathophysiology. MOLBREEVI, if approved, would be the first disease-modifying therapy, addressing a significant unmet medical need in the rare respiratory disease market. The expanded market size estimate further underscores the commercial potential in this underserved patient population.

Comparison to Industry Standards

• MOLBREEVI's ~10% increase from baseline in DLco% at Week 24 and ~12% at Week 48 compares favorably to the minimal clinically important difference (MCID) of 10% in progressive pulmonary fibrosis and 11% in severe COPD, suggesting a clinically meaningful benefit for patients with autoimmune PAP.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong clinical trial results, expanded market opportunity, and clear path to potential commercialization, which could lead to increased revenue and stock value.
• **Patients with Autoimmune PAP:** Highly positive impact as MOLBREEVI offers the potential for the first approved disease-modifying therapy, providing a non-invasive alternative to Whole Lung Lavage and improving quality of life.
• **Healthcare Professionals (Pulmonologists):** Positive impact by providing a new, effective treatment option for a challenging rare disease, supported by strong clinical data and a dedicated testing program (aPAP ClearPath).
• **Payers:** Generally positive, with 87% intending to cover MOLBREEVI, recognizing the significant disease burden and unmet need, despite the anticipated high orphan drug pricing.
• **Employees:** Positive impact through potential growth and expansion of the company as it moves towards commercialization, leading to increased hiring and career opportunities.

Next Steps

• Resubmit Biologics License Application (BLA) for MOLBREEVI in the U.S. in December 2025.
• Continue advancing commercial launch planning activities, including disease awareness campaigns for healthcare professionals and patients.
• Build critical capabilities to facilitate access to MOLBREEVI post-approval, such as establishing an exclusive specialty pharmacy network and developing the MyMolbreevi patient support program.
• Expand the market development team to broaden reach and accelerate pre-launch activities, including profiling accounts and educating on antibody testing.

Key Dates

Recommendation

The filing presents compelling evidence of MOLBREEVI's efficacy and safety in a Phase 3 trial for autoimmune PAP, a rare disease with no approved treatments. The significant expansion of the estimated U.S. market size, coupled with strong stakeholder support (pulmonologists and payers), indicates a substantial commercial opportunity. The company's robust cash position and clear regulatory and commercialization strategy, including 12-year biologic exclusivity, position it for significant future revenue generation. Despite the implied regulatory setback requiring BLA resubmission, the underlying clinical data and market potential are highly favorable, making it a strong investment opportunity.

Keywords

Savara Inc., MOLBREEVI, molgramostim inhalation solution, autoimmune Pulmonary Alveolar Proteinosis, autoimmune PAP, rare respiratory diseases, Phase 3 clinical trial, IMPALA-2, DLco, SGRQ, Biologics License Application, BLA, Orphan Drug Designation, Breakthrough Therapy, eFlow Nebulizer System, drug development, biotechnology, pharmaceuticals, respiratory therapy